Also known as: HGSOC
Pilot genetic testing at ESMO Breast Cancer 2026 found inherited variants in 8.6% of breast and 10.1% of ovarian cancer survivors. A systematic review linked mammographic surveillance to a 50% lower mortality risk.
Preclinical studies reveal that fructose promotes metastasis in ovarian cancer by reducing cell adhesion, while brigatinib enhances PARP inhibitor efficacy by blocking an early adaptive resistance mechanism. The findings suggest dietary modifications and repurposing a lung cancer drug could improve outcomes for high-grade serous ovarian cancer patients.
New studies reveal how cancer cells survive chemotherapy: fructose promotes ovarian cancer spread, platinum-treated 'zombie cells' release TGFβ in lung and ovarian cancers, and mitochondrial metabolism drives 5FU resistance in colorectal cancer. The findings point to potential combination therapy targets.
Homologous recombination deficiency testing and molecular profiling are reshaping treatment strategies for advanced ovarian cancer, guiding PARP inhibitor and bevacizumab maintenance decisions in newly diagnosed patients.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT05281471 |
Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076) |
RECRUITING | PHASE3 |
| NCT05005403 |
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan |
RECRUITING | PHASE1 |
